Israel's D. Medical ($DMED) has signed an original equipment manufacturer agreement with Twobiens, a Korean firm, to market its insulin-delivery technology. The deal, worth up to $5 million over three years, will allow Twobiens to commercialize the Spring Universal Infusion Set, which is compatible with most insulin pumps. D. Medical is touting the infusion tech as a major step forward in diabetes treatment, as it can detect when it has been detached from the body and block off its needle, preventing insulin leakage and making for a safer product. The device already carries approval in the U.S., Canada and Europe. Report